Russia's Biocad ready to commission new flagship facility in St Petersburg region

7 May 2019

Leading Russian drugmaker Biocad plans to commission its new large-scale production facility in the St Petersburg Neudorf special economic zone next month, with the aim to significantly increase its domestic production capacities. according to the company, reports The Pharma Letter’s local correspondent.

The value of investments in the project is estimated at about 2.5 billion roubles ($38.4 million), with the majority of funds invested in the purchase of machinery and equipment for the plant.

It is planned the new plant will be one of the largest in the entire Russian North West region and will focus on the production of a wide range of active ingredients and finished drugs. In the latter case, as part of the company’s plans is launching the production of drugs for the treatment of cancer and autoimmune diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK